Skip to main content

Vera Therapeutics, Inc.

VERA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001831828

In the last 90 days, Vera Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 219 institutions reported holding it in 13F filings for Q2 2026, worth $3.34B in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding Vera Therapeutics, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of VERA: Q1 2022 compared with Q2 2022
MeasureQ1 2022Of which not filed for Q2 2022Q2 2022Change
Holders50151+2
Shares19.7M1.44K20.4M+721.9K (+3.7%)
Value$468.9M$34.0K$277.6M−$191.3M (−40.8%)

1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Vera Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to VERA in Q2 2022
InstitutionSharesValue% of portfolio
Bank of Montreal96,849$1.41M0.00%
Swiss National Bank34,700$472.0K0.00%
Alps Advisors Inc16,060$219.0K0.00%
Dynamic Technology Lab Private Ltd11,939$162.0K0.02%
Credit Suisse AG9,604$131.0K0.00%
State of Wyoming28$00.00%

Sold out (4)

Institutions that held Vera Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of VERA in Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Logos Global Management LP385,000$9.04M
Maven Securities LTD64,240$1.51M
Gyon Technologies Capital Management, LP16,961$398.0K
US Bancorp1,000$23.0K

Not filed for Q2 2022 yet (1)

Institutions that held Vera Therapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding VERA in Q1 2022 that haven't filed for Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Amalgamated Financial Corp.1,438$34.0K